A new health study has assessed a new method for weight loss management, which uses GLP-1. The Microdose GLP-1Rx Program aims to improve health by personalizing the treatment for individuals, to reduce side effects, and mitigate the increased costs of routine use of GLP-1. About 40% of adults in the U.S. are obese. It is the highest in developed countries. This trend highlights the elevation in the demand for sustainable, affordable, and tolerable weight loss interventions.
Dr. Jeffrey Egler, CMO of Noom, said that the company values gradual titration and personalization to decrease the burden of treatment and ensure effectiveness. Gastrointestinal side effects from GLP-1 methods can impede adherence. As per the new model, individuals get 25% of the standard maintenance dosage by a low and slow dosing method.
The individualized dose is based on clinical variables such as the participant’s adjusted body mass index (BMI), rate of weight loss, and tolerance. Internal data from Noom shows that around 70% of participants on microdosed regimens experience no side effects and report a weight loss of 17 lbs in 2 months.
Research is emerging to support the reduced-dose GLP-1 therapy promised. At the 2025 European Congress on Obesity, data analysis of almost 2700 participants demonstrated that microdosing participants taking semaglutide lost an average of 16% body weight at 64 weeks. Another study published in The New England Journal of Medicine demonstrated that one-third of the standard GLP-1 dose resulted in approximately 72% of the weight loss effect and fewer adverse reactions.
Behavioral support is an important component. Participants have access to digital companion platforms to support individual plans with components such as meal tracking, coaching, activity support, and 24-hour access to healthcare. Preliminary analysis has shown that users who are interacting and have high adherence to these platforms are producing an average of 10% weight loss in 4 months in comparison to users who do not regularly engage.
In addition to weight management, GLP-1-based treatment is being researched for its potential benefits on renal, cardiovascular, and inflammatory health and possible effects on compulsive behaviors such as gambling and alcohol use. Noom has announced plans to make a free version of its voluntary app available globally to provide better access to people. They intend to offer evidence-based health capability to all American citizens, regardless of BMI or income. According to the leadership of the organization, the long-term goals transcend weight reduction, and the ecosystem will support metabolic resilience and longevity.
Reference: Noom launches Microdose GLP-1 program, enabling weight loss without the side effects and priced at $119 to start, including medication and Microhabits program.Noom. Published August 4, 2025. https://www.noom.com/blog/weight-management/why-we-launched-noom-microdose-glp-1rx/
